

Virginia M-Y Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8873922/publications.pdf>

Version: 2024-02-01

304
papers

71,947
citations

735

120
h-index

632

257
g-index

308
all docs

308
docs citations

308
times ranked

40411
citing authors

#	ARTICLE	IF	CITATIONS
1	Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. <i>Cell</i> , 2022, 185, 712-728.e14.	28.9	114
2	Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology. <i>Current Opinion in Neurobiology</i> , 2022, 72, 171-177.	4.2	5
3	Inhibition of CK2 mitigates Alzheimer's tau pathology by preventing NR2B synaptic mislocalization. <i>Acta Neuropathologica Communications</i> , 2022, 10, 30.	5.2	8
4	Single-nuclei isoform RNA sequencing unlocks barcoded exon connectivity in frozen brain tissue. <i>Nature Biotechnology</i> , 2022, 40, 1082-1092.	17.5	52
5	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. <i>Acta Neuropathologica</i> , 2022, 143, 15-31.	7.7	29
6	Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2022, 10, 75.	5.2	3
7	Fluent molecular mixing of Tau isoforms in Alzheimer's disease neurofibrillary tangles. <i>Nature Communications</i> , 2022, 13, .	12.8	27
8	High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. <i>Neuron</i> , 2021, 109, 42-58.e8.	8.1	157
9	In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics. <i>Acta Neuropathologica</i> , 2021, 141, 193-215.	7.7	30
10	Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5- <i>a</i>]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 1073-1102.	6.4	17
11	Distinct brain-derived TDP-43 strains from FTLD-TDP subtypes induce diverse morphological TDP-43 aggregates and spreading patterns <i>in vitro</i> and <i>in vivo</i> . <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1033-1049.	3.2	25
12	Poly (ADP-ribose) Interacts With Phosphorylated \pm -Synuclein in Post Mortem PD Samples. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 704041.	3.4	14
13	Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor. <i>Science Advances</i> , 2021, 7, .	10.3	30
14	TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. <i>Acta Neuropathologica</i> , 2021, 142, 629-642.	7.7	15
15	Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery. <i>Acta Neuropathologica Communications</i> , 2021, 9, 140.	5.2	25
16	LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1187-1196.	2.8	5
17	Effects of microglial depletion and TREM2 deficiency on A β plaque burden and neuritic plaque tau pathology in 5XFAD mice. <i>Acta Neuropathologica Communications</i> , 2021, 9, 150.	5.2	19
18	The development and convergence of co-pathologies in Alzheimer's disease. <i>Brain</i> , 2021, 144, 953-962.	7.6	76

#	ARTICLE	IF	CITATIONS
19	Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor. <i>Brain Communications</i> , 2021, 3, fcab011.	3.3	41
20	Î±-Synuclein modulates tau spreading in mouse brains. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	49
21	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. <i>Neurology: Clinical Practice</i> , 2021, 11, 105-116.	1.6	5
22	Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. <i>Acta Neuropathologica Communications</i> , 2021, 9, 188.	5.2	29
23	AD-linked R47H- <i>TREM2</i> mutation induces disease-enhancing microglial states via AKT hyperactivation. <i>Science Translational Medicine</i> , 2021, 13, eabe3947.	12.4	55
24	Transmission of tauopathy strains is independent of their isoform composition. <i>Nature Communications</i> , 2020, 11, 7.	12.8	121
25	Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological Î±-Synuclein Insult. <i>Neuron</i> , 2020, 105, 822-836.e7.	8.1	89
26	Amyloid-Beta (AÎ²) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with AÎ² Pathology. <i>Neuron</i> , 2020, 105, 260-275.e6.	8.1	141
27	Characterization of novel conformation-selective Î±-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104712.	4.4	31
28	Characterization of tau binding by gosuranemab. <i>Neurobiology of Disease</i> , 2020, 146, 105120.	4.4	36
29	Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. <i>Acta Neuropathologica</i> , 2020, 140, 831-849.	7.7	37
30	Defining and predicting transdiagnostic categories of neurodegenerative disease. <i>Nature Biomedical Engineering</i> , 2020, 4, 787-800.	22.5	22
31	An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. <i>Nature Communications</i> , 2020, 11, 5522.	12.8	56
32	Modulating TRADD to restore cellular homeostasis and inhibit apoptosis. <i>Nature</i> , 2020, 587, 133-138.	27.8	57
33	Correction of microtubule defects within AÎ² plaque-associated dystrophic axons results in lowered AÎ² release and plaque deposition. <i>Alzheimer's and Dementia</i> , 2020, 16, 1345-1357.	0.8	11
34	Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 941-949.	1.7	6
35	Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 64.	10.8	19
36	Cell-to-Cell Transmission of Tau and Î±-Synuclein. <i>Trends in Molecular Medicine</i> , 2020, 26, 936-952.	6.7	91

#	ARTICLE	IF	CITATIONS
37	Distribution patterns of tau pathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2020, 140, 99-119.	7.7	210
38	Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer's disease. <i>Brain</i> , 2020, 143, 1572-1587.	7.6	50
39	The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of A β 242 and Its Protein Aggregates. <i>Molecular Neurobiology</i> , 2020, 57, 3803-3813.	4.0	49
40	Protein transmission in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2020, 16, 199-212.	10.1	330
41	Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. <i>Npj Vaccines</i> , 2020, 5, 28.	6.0	15
42	Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex. <i>Acta Neuropathologica</i> , 2020, 140, 591-593.	7.7	4
43	Synthesis and characterization of high affinity fluorogenic β -synuclein probes. <i>Chemical Communications</i> , 2020, 56, 3567-3570.	4.1	24
44	Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays. <i>Journal of Biological Chemistry</i> , 2020, 295, 4001-4013.	3.4	10
45	Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 80.	3.4	139
46	Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	73
47	Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 1912-1930.	8.2	268
48	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019, 85, 259-271.	5.3	88
49	Cerebrospinal Fluid Total and Phosphorylated β -Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy. <i>Molecular Neurobiology</i> , 2019, 56, 3476-3483.	4.0	26
50	C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. <i>Acta Neuropathologica</i> , 2019, 138, 795-811.	7.7	50
51	Spread of β -synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. <i>Nature Neuroscience</i> , 2019, 22, 1248-1257.	14.8	187
52	Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer's disease patient brain samples. <i>Acta Neuropathologica</i> , 2019, 138, 613-630.	7.7	68
53	Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. <i>Journal of Biological Chemistry</i> , 2019, 294, 12754-12765.	3.4	114
54	Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. <i>Brain</i> , 2019, 142, 3565-3579.	7.6	80

#	ARTICLE	IF	CITATIONS
55	Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (α -Syn) Pathology in Synthetic α -Syn Fibril-Induced Mouse Models of Synucleinopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 877-890.	1.7	46
56	Genetic predictors of survival in behavioral variant frontotemporal degeneration. <i>Neurology</i> , 2019, 93, e1707-e1714.	1.1	11
57	TREM2 function impedes tau seeding in neuritic plaques. <i>Nature Neuroscience</i> , 2019, 22, 1217-1222.	14.8	190
58	α -Synuclein pathology in Parkinson's disease and related α -synucleinopathies. <i>Neuroscience Letters</i> , 2019, 709, 134316.	2.1	177
59	Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 65.	5.2	20
60	α -Synuclein (α -Syn) Preformed Fibrils Induce Endogenous α -Syn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons. <i>Journal of Neuroscience</i> , 2019, 39, 5080-5094.	3.6	76
61	eIF4B and eIF4H mediate GR production from expanded G4C2 in a Drosophila model for C9orf72-associated ALS. <i>Acta Neuropathologica Communications</i> , 2019, 7, 62.	5.2	38
62	Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). <i>Acta Neuropathologica Communications</i> , 2019, 7, 34.	5.2	27
63	LRRK2 inhibition does not impart protection from α -synuclein pathology and neuron death in non-transgenic mice. <i>Acta Neuropathologica Communications</i> , 2019, 7, 28.	5.2	39
64	Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils. <i>Methods in Molecular Biology</i> , 2019, 1948, 45-57.	0.9	21
65	Transmission of α -synuclein seeds in neurodegenerative disease: recent developments. <i>Laboratory Investigation</i> , 2019, 99, 971-981.	3.7	74
66	Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 183.	5.2	101
67	Neuroimmune interactions in Alzheimer's disease—New frontier with old challenges?. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 183-201.	1.7	12
68	Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	30
69	Mechanisms of Cell-to-Cell Transmission of Pathological Tau. <i>JAMA Neurology</i> , 2019, 76, 101.	9.0	162
70	Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. <i>Neurobiology of Disease</i> , 2019, 124, 133-140.	4.4	28
71	A "Clickable" Photoconvertible Small Fluorescent Molecule as a Minimalist Probe for Tracking Individual Biomolecule Complexes. <i>Journal of the American Chemical Society</i> , 2019, 141, 1893-1897.	13.7	40
72	Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 55-64.	0.8	97

#	ARTICLE	IF	CITATIONS
73	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019, 76, 318.	9.0	161
74	UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2019, 73, 190-199.	3.1	31
75	Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. <i>Nature Neuroscience</i> , 2018, 21, 329-340.	14.8	220
76	Measurements of autoantibodies to α -synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. <i>Journal of Neurochemistry</i> , 2018, 145, 489-503.	3.9	47
77	Differential α -synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. <i>Acta Neuropathologica</i> , 2018, 135, 855-875.	7.7	94
78	Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 216-228.	1.7	69
79	Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. <i>Brain</i> , 2018, 141, 288-301.	7.6	56
80	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018, 136, 363-376.	7.7	114
81	Distinct α -Synuclein strains and implications for heterogeneity among α -Synucleinopathies. <i>Neurobiology of Disease</i> , 2018, 109, 209-218.	4.4	121
82	Spread of aggregates after olfactory bulb injection of α -synuclein fibrils is associated with early neuronal loss and is reduced long term. <i>Acta Neuropathologica</i> , 2018, 135, 65-83.	7.7	154
83	P1439: THE CONTRIBUTION OF SEX-SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P327.	0.8	0
84	A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. <i>Molecular Neurodegeneration</i> , 2018, 13, 59.	10.8	27
85	Aberrant activation of non-coding RNA targets of transcriptional elongation complexes contributes to TDP-43 toxicity. <i>Nature Communications</i> , 2018, 9, 4406.	12.8	40
86	Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. <i>Nature Communications</i> , 2018, 9, 4220.	12.8	176
87	Converging Patterns of α -Synuclein Pathology in Multiple System Atrophy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 1005-1016.	1.7	26
88	Amyloid- β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. <i>Nature Medicine</i> , 2018, 24, 29-38.	30.7	433
89	Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 857-872.	7.7	87
90	Sequential stages and distribution patterns of aging-related tau astroglial pathology (ARTAG) in the human brain. <i>Acta Neuropathologica Communications</i> , 2018, 6, 50.	5.2	77

#	ARTICLE	IF	CITATIONS
91	Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. <i>Journal of Parkinson's Disease</i> , 2018, 8, 303-322.	2.8	151
92	Cellular milieu imparts distinct pathological α -synuclein strains in α -synucleinopathies. <i>Nature</i> , 2018, 557, 558-563.	27.8	457
93	LRRK2 activity does not dramatically alter α -synuclein pathology in primary neurons. <i>Acta Neuropathologica Communications</i> , 2018, 6, 45.	5.2	34
94	TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. <i>Journal of Experimental Medicine</i> , 2018, 215, 2355-2377.	8.5	173
95	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018, 141, 2181-2193.	7.6	448
96	Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study. <i>Acta Neuropathologica</i> , 2018, 136, 377-388.	7.7	112
97	Selective imaging of internalized proteopathic α -synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. <i>Journal of Biological Chemistry</i> , 2017, 292, 13482-13497.	3.4	131
98	Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies. <i>Journal of Neuroscience</i> , 2017, 37, 5870-5884.	3.6	30
99	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
100	Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 270-288.	1.7	98
101	Novel conformation-selective α -synuclein antibodies raised against different <i>in vitro</i> fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 604-620.	3.2	51
102	Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. <i>Neurobiology of Disease</i> , 2017, 105, 328-335.	4.4	74
103	GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils. <i>Journal of Neuroscience</i> , 2017, 37, 11485-11494.	3.6	28
104	Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain. <i>Journal of Neuroscience</i> , 2017, 37, 11406-11423.	3.6	284
105	Modeling Parkinson's disease pathology by combination of fibril seeds and α -synuclein overexpression in the rat brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8284-E8293.	7.1	161
106	[PLA α 04 α 02 α 01]: CELL-TO-CELL TRANSMISSION OF PATHOLOGICAL TAU: A POTENTIAL MECHANISM OF DISEASE PROGRESSION IN ALZHEIMER'S AND OTHER TAUOPATHIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1224.	0.8	0
107	TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. <i>Current Biology</i> , 2017, 27, 3579-3590.e6.	3.9	63
108	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. <i>Brain</i> , 2017, 140, aww339.	7.6	153

#	ARTICLE	IF	CITATIONS
109	Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 864-868.	2.8	32
110	TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. <i>Neuron</i> , 2017, 95, 297-308.e6.	8.1	171
111	The use of mouse models to study cell-to-cell transmission of pathological tau. <i>Methods in Cell Biology</i> , 2017, 141, 287-305.	1.1	14
112	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. <i>Acta Neuropathologica Communications</i> , 2017, 5, 68.	5.2	34
113	Deep clinical and neuropathological phenotyping of ^Pick disease. <i>Annals of Neurology</i> , 2016, 79, 272-287.	5.3	146
114	Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. <i>Scientific Reports</i> , 2016, 6, 34904.	3.3	67
115	P2â€163: Performance Evaluation of New Absorbanceâ€Based Elisass for Measuring Different Alphaâ€Synuclein (Aâ€SYN) Species in CSF and Plasma. <i>Alzheimer's and Dementia</i> , 2016, 12, P677.	0.8	1
116	ICâ€Pâ€186: [^{11C}]PBB3 PET Visualizes TAU Aggregates in Patients with FTDPâ€17 MAPT Gene Mutation. <i>Alzheimer's and Dementia</i> , 2016, 12, P135.	0.8	2
117	The Dynamics and Turnover of Tau Aggregates in Cultured Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 13175-13193.	3.4	59
118	Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. <i>Cell Reports</i> , 2016, 16, 3373-3387.	6.4	141
119	Cognitive reserve in frontotemporal degeneration. <i>Neurology</i> , 2016, 87, 1813-1819.	1.1	40
120	Widespread transneuronal propagation of Î±-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinsonâ€™s disease. <i>Journal of Experimental Medicine</i> , 2016, 213, 1759-1778.	8.5	309
121	Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy. <i>Journal of Neuroscience</i> , 2016, 36, 7707-7717.	3.6	62
122	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P252.	0.8	0
123	Unique pathological tau conformers from Alzheimerâ€™s brains transmit tau pathology in nontransgenic mice. <i>Journal of Experimental Medicine</i> , 2016, 213, 2635-2654.	8.5	310
124	Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. <i>Alzheimer's and Dementia</i> , 2016, 12, 1051-1065.	0.8	91
125	Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 106.	5.2	45
126	Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 935-937.	7.7	81

#	ARTICLE	IF	CITATIONS
127	Progression of motor neuron disease is accelerated and the ability to recover is compromised with advanced age in rNLS8 mice. <i>Acta Neuropathologica Communications</i> , 2016, 4, 105.	5.2	16
128	Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. <i>Neuron</i> , 2016, 91, 41-55.	8.1	75
129	Solid-state NMR structure of a pathogenic fibril of full-length human α -synuclein. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 409-415.	8.2	802
130	Comparison of strategies for non-perturbing labeling of α -synuclein to study amyloidogenesis. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 1584-1592.	2.8	37
131	Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members. <i>PLoS ONE</i> , 2016, 11, e0168913.	2.5	16
132	Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His. <i>Acta Neuropathologica Communications</i> , 2015, 3, 42.	5.2	14
133	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. <i>Acta Neuropathologica</i> , 2015, 129, 469-491.	7.7	218
134	Spreading of pathology in neurodegenerative diseases: a focus on human studies. <i>Nature Reviews Neuroscience</i> , 2015, 16, 109-120.	10.2	611
135	Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. <i>Acta Neuropathologica</i> , 2015, 130, 643-660.	7.7	215
136	Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections. <i>Acta Neuropathologica</i> , 2015, 130, 349-362.	7.7	174
137	Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. <i>Acta Neuropathologica</i> , 2015, 129, 221-237.	7.7	211
138	Drosha Inclusions Are New Components of Dipeptide-Repeat Protein Aggregates in FTLD-TDP and ALSC9orf72 Expansion Cases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 380-387.	1.7	28
139	High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration. <i>Acta Neuropathologica Communications</i> , 2015, 3, 33.	5.2	18
140	An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. <i>Human Molecular Genetics</i> , 2015, 24, 7241-7254.	2.9	39
141	Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. <i>Neurobiology of Disease</i> , 2015, 73, 83-95.	4.4	168
142	Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models. <i>PLoS ONE</i> , 2015, 10, e0125614.	2.5	124
143	Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal Dysregulation of Histone Transcripts and Nuclear Chromatin. <i>PLoS ONE</i> , 2015, 10, e0141836.	2.5	40
144	Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. <i>Brain</i> , 2014, 137, 2578-2587.	7.6	132

#	ARTICLE	IF	CITATIONS
145	Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. <i>Neurology</i> , 2014, 83, 502-509.	1.1	26
146	Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. <i>EMBO Molecular Medicine</i> , 2014, 6, 1142-1160.	6.9	297
147	Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 442.	9.0	74
148	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). <i>Acta Neuropathologica</i> , 2014, 127, 423-439.	7.7	237
149	Modeling Lewy pathology propagation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S85-S87.	2.2	104
150	Therapeutic modulation of eIF2 γ phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. <i>Nature Genetics</i> , 2014, 46, 152-160.	21.4	321
151	Formation of α -synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. <i>Molecular Biology of the Cell</i> , 2014, 25, 4010-4023.	2.1	202
152	Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. <i>Nature Medicine</i> , 2014, 20, 130-138.	30.7	547
153	α -Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α -Synuclein and Neurodegeneration. <i>Cell Reports</i> , 2014, 7, 2054-2065.	6.4	287
154	In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy. <i>NeuroImage</i> , 2014, 101, 185-192.	4.2	57
155	Addition of exogenous α -synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α -synuclein to Lewy body and Lewy neurite-like aggregates. <i>Nature Protocols</i> , 2014, 9, 2135-2146.	12.0	496
156	Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. <i>Acta Neuropathologica Communications</i> , 2014, 2, 33.	5.2	25
157	Potent, Long-Acting Cyclopentane-1,3-Dione Thromboxane (A ₂)-Receptor Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1015-1020.	2.8	6
158	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014, 10, 477.	0.8	167
159	Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5040-5049.	3.0	87
160	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2014, 35, 1473-1482.	3.1	43
161	Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. <i>Nature Reviews Neuroscience</i> , 2013, 14, 626-636.	10.2	673
162	MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 886-889.	2.8	33

#	ARTICLE	IF	CITATIONS
163	Lewy Body-like β -Synuclein Aggregates Resist Degradation and Impair Macroautophagy. Journal of Biological Chemistry, 2013, 288, 15194-15210.	3.4	254
164	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. Journal of Comparative Neurology, 2013, 521, 4339-4355.	1.6	47
165	Therapeutic strategies for tau mediated neurodegeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 784-795.	1.9	115
166	Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons overexpressing mutant tau. FEBS Letters, 2013, 587, 717-723.	2.8	91
167	Acetylated Tau Neuropathology in Sporadic and Hereditary Tauopathies. American Journal of Pathology, 2013, 183, 344-351.	3.8	104
168	Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy. Journal of Neuroscience, 2013, 33, 1024-1037.	3.6	548
169	Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone. JAMA Neurology, 2013, 70, 462.	9.0	153
170	Stages of pTDP43 pathology in amyotrophic lateral sclerosis. Annals of Neurology, 2013, 74, 20-38.	5.3	820
171	Calcium Entry and β -Synuclein Inclusions Elevate Dendritic Mitochondrial Oxidant Stress in Dopaminergic Neurons. Journal of Neuroscience, 2013, 33, 10154-10164.	3.6	174
172	Distinct β -Synuclein Strains Differentially Promote Tau Inclusions in Neurons. Cell, 2013, 154, 103-117.	28.9	574
173	Intracerebral inoculation of pathological β -synuclein initiates a rapidly progressive neurodegenerative β -synucleinopathy in mice. Journal of Experimental Medicine, 2012, 209, 975-986.	8.5	910
174	Pathological β -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. Science, 2012, 338, 949-953.	12.6	2,024
175	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	5.3	401
176	A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research. , 2012, 8, 564-573.		16
177	Cardiovascular risk factors, cortisol, and amyloid β deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 483-489.	0.8	113
178	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain, 2012, 135, 807-818.	7.6	226
179	The Microtubule-Stabilizing Agent, Etoposide D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. Journal of Neuroscience, 2012, 32, 3601-3611.	3.6	325
180	Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nature Reviews Neuroscience, 2012, 13, 38-50.	10.2	568

#	ARTICLE	IF	CITATIONS
181	Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. <i>Acta Neuropathologica</i> , 2012, 123, 825-839.	7.7	164
182	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2012, 123, 395-407.	7.7	104
183	A "Two-hit" Hypothesis for Inclusion Formation by Carboxyl-terminal Fragments of TDP-43 Protein Linked to RNA Depletion and Impaired Microtubule-dependent Transport. <i>Journal of Biological Chemistry</i> , 2011, 286, 18845-18855.	3.4	98
184	The acetylation of tau inhibits its function and promotes pathological tau aggregation. <i>Nature Communications</i> , 2011, 2, 252.	12.8	554
185	Exogenous α -Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death. <i>Neuron</i> , 2011, 72, 57-71.	8.1	1,249
186	Phiel et al. reply. <i>Nature</i> , 2011, 480, E6-E6.	27.8	1
187	Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 726-738.	8.2	343
188	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. <i>Acta Neuropathologica</i> , 2011, 121, 597-609.	7.7	256
189	Aggregation of α -Synuclein in <i>S. cerevisiae</i> is Associated with Defects in Endosomal Trafficking and Phospholipid Biosynthesis. <i>Journal of Molecular Neuroscience</i> , 2011, 43, 391-405.	2.3	71
190	Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles. <i>Journal of Biological Chemistry</i> , 2011, 286, 15317-15331.	3.4	538
191	Developing Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal Protein Targets. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a006437-a006437.	6.2	101
192	<i>In Vivo</i> Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice. <i>Journal of Neuroscience</i> , 2011, 31, 13110-13117.	3.6	309
193	Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. <i>Acta Neuropathologica</i> , 2010, 119, 409-419.	7.7	308
194	Characterization of tau fibrillization in vitro. <i>Alzheimer's and Dementia</i> , 2010, 6, 110-117.	0.8	52
195	Forebrain overexpression of α -synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. <i>Experimental Neurology</i> , 2010, 221, 86-97.	4.1	31
196	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. <i>Alzheimer's and Dementia</i> , 2010, 6, 230-238.	0.8	256
197	β Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model. <i>American Journal of Pathology</i> , 2010, 177, 1977-1988.	3.8	179
198	TAR DNA-binding protein 43 in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2010, 6, 211-220.	10.1	396

#	ARTICLE	IF	CITATIONS
199	Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. <i>Journal of Biological Chemistry</i> , 2009, 284, 8516-8524.	3.4	304
200	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. <i>Annals of Neurology</i> , 2009, 65, 403-413.	5.3	1,803
201	Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. <i>Acta Neuropathologica</i> , 2009, 117, 137-149.	7.7	466
202	Exogenous α -synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20051-20056.	7.1	783
203	Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies. <i>Archives of Neurology</i> , 2009, 66, 180-9.	4.5	232
204	TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. <i>Acta Neuropathologica</i> , 2008, 115, 305-311.	7.7	58
205	Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>American Journal of Pathology</i> , 2008, 173, 182-194.	3.8	284
206	Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 636-41.	4.5	251
207	TDP-43 Proteinopathies: Neurodegenerative Protein Misfolding Diseases without Amyloidosis. <i>NeuroSignals</i> , 2008, 16, 41-51.	0.9	115
208	Disturbance of Nuclear and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and Aggregate Formation. <i>Journal of Biological Chemistry</i> , 2008, 283, 13302-13309.	3.4	509
209	Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 555-564.	1.7	328
210	TDP-43 immunoreactivity in anoxic, ischemic and proliferating lesion of the central nervous system. <i>FASEB Journal</i> , 2008, 22, 708.13.	0.5	0
211	Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. <i>Neuron</i> , 2007, 53, 337-351.	8.1	1,696
212	Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. <i>Nature Reviews Neuroscience</i> , 2007, 8, 663-672.	10.2	1,866
213	Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual. <i>Acta Neuropathologica</i> , 2007, 113, 471-479.	7.7	12
214	Mechanisms of slow axonal transport of α -synuclein. <i>FASEB Journal</i> , 2007, 21, A28.	0.5	0
215	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>Science</i> , 2006, 314, 130-133.	12.6	5,422
216	Pathological Heterogeneity of Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions Delineated by Ubiquitin Immunohistochemistry and Novel Monoclonal Antibodies. <i>American Journal of Pathology</i> , 2006, 169, 1343-1352.	3.8	296

#	ARTICLE	IF	CITATIONS
217	Characterization of Two VQIXXX Motifs for Tau Fibrillization in Vitro. Biochemistry, 2006, 45, 15692-15701.	2.5	159
218	Mechanisms of Parkinson's Disease Linked to Pathological β -Synuclein: New Targets for Drug Discovery. Neuron, 2006, 52, 33-38.	8.1	437
219	Frontotemporal lobar degeneration. , 2005, , 481-493.		1
220	Transgenic animal models of tauopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 251-259.	3.8	118
221	Mouse Model of Multiple System Atrophy β -Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration. Neuron, 2005, 45, 847-859.	8.1	277
222	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. Journal of Neurochemistry, 2004, 90, 1541-1541.	3.9	1
223	More than just two peas in a pod: common amyloidogenic properties of tau and β -synuclein in neurodegenerative diseases. Trends in Neurosciences, 2004, 27, 129-134.	8.6	177
224	Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of diseases with β -synuclein inclusions. , 2004, , 353-375.		5
225	Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathologica, 2003, 106, 243-250.	7.7	36
226	Role of β -Synuclein Carboxy-Terminus on Fibril Formation in Vitro. Biochemistry, 2003, 42, 8530-8540.	2.5	314
227	Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein. Science, 2003, 300, 636-640.	12.6	791
228	Ubiquitination of β -Synuclein Is Not Required for Formation of Pathological Inclusions in β -Synucleinopathies. American Journal of Pathology, 2003, 163, 91-100.	3.8	129
229	Secretion and Intracellular Generation of Truncated $A\beta$ in β -Site Amyloid- β Precursor Protein-cleaving Enzyme Expressing Human Neurons. Journal of Biological Chemistry, 2003, 278, 4458-4466.	3.4	75
230	Research on the Brain. Science of Aging Knowledge Environment: SAGE KE, 2003, 2003, 29pe-29.	0.8	1
231	Signature Tau Neuropathology in Gray and White Matter of Corticobasal Degeneration. American Journal of Pathology, 2002, 160, 2045-2053.	3.8	136
232	Neuronal β -Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human β -Synuclein. Neuron, 2002, 34, 521-533.	8.1	1,094
233	Amyloid binding ligands as Alzheimer's disease therapies. Neurobiology of Aging, 2002, 23, 1039-1042.	3.1	83
234	Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Annals of Neurology, 2002, 51, 182-189.	5.3	232

#	ARTICLE	IF	CITATIONS
235	Sporadic Pick's disease: A tauopathy characterized by a spectrum of pathological τ isoforms in gray and white matter. <i>Annals of Neurology</i> , 2002, 51, 730-739.	5.3	141
236	Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. <i>Annals of Neurology</i> , 2002, 52, 205-210.	5.3	300
237	Tau and Axonopathy in Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2002, 2, 131-150.	3.4	120
238	Neurodegenerative Tauopathies. <i>Annual Review of Neuroscience</i> , 2001, 24, 1121-1159.	10.7	2,416
239	A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of β -Synuclein Is Essential for Filament Assembly. <i>Journal of Biological Chemistry</i> , 2001, 276, 2380-2386.	3.4	865
240	The Fluorescent Congo Red Derivative, (Trans,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 552 Td (Trans) β -1-Bromo-2,5-Bis-(3-Hydroxycarbon Sheet Structures in Postmortem Human Neurodegenerative Disease Brains. <i>American Journal of Pathology</i> , 2001, 159, 937-943.	3.8	81
241	Frontotemporal dementia and tauopathy. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 413-421.	4.2	32
242	Oxidative post-translational modifications of β -synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2001, 76, 637-640.	3.9	184
243	Neuronal localization of the TNF α converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. <i>Journal of Neurobiology</i> , 2001, 49, 40-46.	3.6	79
244	Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. <i>Annals of Neurology</i> , 2001, 49, 165-175.	5.3	159
245	Lewy Body Pathology in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2001, 17, 225-232.	2.3	138
246	Synucleins Are Developmentally Expressed, and β -Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons. <i>Journal of Neuroscience</i> , 2000, 20, 3214-3220.	3.6	795
247	Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of β -Synuclein Permutations in Multiple System Atrophy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 830-841.	1.7	135
248	Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. <i>Cancer</i> , 2000, 88, 2154-2163.	4.1	145
249	Neuropathology of synuclein aggregates. <i>Journal of Neuroscience Research</i> , 2000, 61, 121-127.	2.9	275
250	β -synuclein is developmentally expressed in cultured rat brain oligodendrocytes. <i>Journal of Neuroscience Research</i> , 2000, 62, 9-14.	2.9	125
251	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. <i>Annals of Neurology</i> , 2000, 48, 77-87.	5.3	310
252	Frontotemporal dementia with novel tau pathology and a Glu342Valtau mutation. <i>Annals of Neurology</i> , 2000, 48, 850-858.	5.3	97

#	ARTICLE	IF	CITATIONS
253	A new link between pesticides and Parkinson's disease. Nature Neuroscience, 2000, 3, 1227-1228.	14.8	67
254	Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment. Journal of Histochemistry and Cytochemistry, 2000, 48, 1627-1637.	2.5	77
255	A Distinct ER/IC β -Secretase Competes with the Proteasome for Cleavage of APP. Biochemistry, 2000, 39, 810-817.	2.5	81
256	"Fatal Attractions" of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders. Annals of the New York Academy of Sciences, 2000, 924, 62-67.	3.8	154
257	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. , 2000, 48, 77.		1
258	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Annals of Neurology, 2000, 48, 77-87.	5.3	4
259	Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. Annals of Neurology, 2000, 48, 850-858.	5.3	5
260	Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Annals of Neurology, 1999, 45, 174-181.	5.3	121
261	Antibodies to β -synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Annals of Neurology, 1999, 45, 353-357.	5.3	289
262	From genotype to phenotype: A clinical, pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation. Annals of Neurology, 1999, 45, 704-715.	5.3	128
263	Mice with disrupted midsize and heavy neurofilament genes lack axonal neurofilaments but have unaltered numbers of axonal microtubules. , 1999, 57, 23-32.		33
264	Neurofilaments of aged rats: The strengthened interneurofilament interaction and the reduced amount of NF-M. Journal of Neuroscience Research, 1999, 58, 337-348.	2.9	14
265	Functional synapses are formed between human NTera2 (NT2N, hNT) neurons grown on astrocytes. , 1999, 407, 1-10.		131
266	Differential effects of spinal cord gray and white matter on process outgrowth from grafted human NTERA2 neurons (NT2N, hNT). , 1999, 415, 404-418.		36
267	[6] Purification of paired helical filament tau and normal tau from human brain tissue. Methods in Enzymology, 1999, 309, 81-89.	1.0	48
268	Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform. Neuron, 1999, 24, 751-762.	8.1	564
269	Accumulation of Intracellular Amyloid- β Peptide ($A\beta$ 1-40) in Mucopolysaccharidosis Brains. Journal of Neuropathology and Experimental Neurology, 1999, 58, 815-824.	1.7	52
270	Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Annals of Neurology, 1999, 45, 174-181.	5.3	4

#	ARTICLE	IF	CITATIONS
271	Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. <i>Cell Death and Differentiation</i> , 1998, 5, 832-837.	11.2	272
272	Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease. <i>Annals of Neurology</i> , 1998, 43, 259-265.	5.3	55
273	Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α -synuclein. <i>Annals of Neurology</i> , 1998, 44, 415-422.	5.3	633
274	Twofold overexpression of human α -amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury. , 1998, 392, 428-438.		83
275	Neurotrophins and neuronal versus glial differentiation in medulloblastomas and other pediatric brain tumors. <i>Acta Neuropathologica</i> , 1998, 95, 325-332.	7.7	32
276	RNA sequestration to pathological lesions of neurodegenerative diseases. <i>Acta Neuropathologica</i> , 1998, 96, 487-494.	7.7	126
277	Lewy Bodies Contain Altered α -Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes. <i>American Journal of Pathology</i> , 1998, 153, 1365-1370.	3.8	484
278	Increased F_2 -isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation <i>in vivo</i> . <i>FASEB Journal</i> , 1998, 12, 1777-1783.	0.5	396
279	Neurofilaments and Orthograde Transport Are Reduced in Ventral Root Axons of Transgenic Mice that Express Human SOD1 with a G93A Mutation. <i>Journal of Cell Biology</i> , 1997, 139, 1307-1315.	5.2	267
280	Effect of Genetic Risk Factors and Disease Progression on the Cerebrospinal Fluid Tau Levels in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 1228-1231.	2.6	18
281	Unique Alzheimer's Disease Paired Helical Filament Specific Epitopes Involve Double Phosphorylation at Specific Sites. <i>Biochemistry</i> , 1997, 36, 8114-8124.	2.5	154
282	α -Synuclein in Lewy bodies. <i>Nature</i> , 1997, 388, 839-840.	27.8	7,181
283	Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. <i>Annals of Neurology</i> , 1997, 41, 200-209.	5.3	153
284	Monoclonal antibodies to purified cortical lewy bodies recognize the mid-size neurofilament subunit. <i>Annals of Neurology</i> , 1997, 42, 595-603.	5.3	48
285	Neurotrophin signal transduction in medulloblastoma. <i>Journal of Neuroscience Research</i> , 1997, 49, 522-527.	2.9	25
286	Dramatic Increase of the RNA Editing for Glutamate Receptor Subunits During Terminal Differentiation of Clonal Human Neurons. <i>Journal of Neurochemistry</i> , 1997, 69, 43-52.	3.9	36
287	Neurotrophin signal transduction in medulloblastoma. <i>Journal of Neuroscience Research</i> , 1997, 49, 522-527.	2.9	1
288	The effects of aspartic acid α -bond isomerization on <i>in vitro</i> properties of the amyloid β -peptide as modeled with N -terminal decapeptide fragments. <i>International Journal of Peptide and Protein Research</i> , 1996, 47, 289-296.	0.1	26

#	ARTICLE	IF	CITATIONS
289	Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease. <i>Annals of Neurology</i> , 1995, 38, 649-652.	5.3	293
290	Neurofilament sidearm proteolysis is a prominent early effect of axotomy in lamprey giant central neurons. <i>Journal of Comparative Neurology</i> , 1995, 353, 38-49.	1.6	49
291	Expression of τ receptors in the developing and adult human central and peripheral nervous system. <i>Journal of Comparative Neurology</i> , 1995, 356, 387-397.	1.6	96
292	Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain. <i>Journal of Comparative Neurology</i> , 1995, 357, 618-632.	1.6	182
293	τ , Phosphorylation in Human, Primate, and Rat Brain: Evidence that a Pool of τ , Is Highly Phosphorylated In Vivo and Is Rapidly Dephosphorylated In Vitro. <i>Journal of Neurochemistry</i> , 1994, 63, 2279-2287.	3.9	69
294	Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. <i>FEBS Journal</i> , 1993, 211, 249-257.	0.2	110
295	Altered τ and Neurofilament Proteins in Neurodegenerative Diseases: Diagnostic Implications for Alzheimer's Disease and Lewy Body Dementias. <i>Brain Pathology</i> , 1993, 3, 45-54.	4.1	230
296	A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau. <i>Science</i> , 1991, 251, 675-678.	12.6	1,441
297	Neurofilament reassembly in vitro: biochemical, morphological and immuno-electron microscopic studies employing monoclonal antibodies to defined epitopes. <i>Brain Research</i> , 1991, 556, 181-195.	2.2	41
298	Individual neurofilament subunits reassembled in vitro exhibit unique biochemical, morphological and immunological properties. <i>Brain Research</i> , 1991, 556, 196-208.	2.2	34
299	The Differential Role of Protein Kinase C Isozyme in the Rapid Induction of Neurofilament Phosphorylation by Nerve Growth Factor and Phorbol Esters in PC12 Cells. <i>Journal of Neurochemistry</i> , 1991, 57, 802-810.	3.9	29
300	Inhibition of axonal development after injection of neurofilament antibodies into a <i>Xenopus laevis</i> embryo. <i>Journal of Comparative Neurology</i> , 1991, 308, 576-585.	1.6	38
301	Molecular milestones that signal axonal maturation and the commitment of human spinal cord precursor cells to the neuronal or glial phenotype in development. <i>Journal of Comparative Neurology</i> , 1991, 310, 285-299.	1.6	93
302	Human olfactory epithelium in normal aging, alzheimer's disease, and other neurodegenerative disorders. <i>Journal of Comparative Neurology</i> , 1991, 310, 365-376.	1.6	115
303	Domain structure of neurofilament subunits as revealed by monoclonal antibodies. <i>Journal of Cellular Biochemistry</i> , 1985, 27, 181-187.	2.6	5
304	Neurofilament breakdown products in degenerating rat and human peripheral nerves. <i>Annals of Neurology</i> , 1984, 16, 349-355.	5.3	21